A. Prat, M. J. Ellis, and C. M. Perou, Practical implications of gene-expressionbased assays for breast oncologists, Nat Rev Clin Oncol, vol.9, pp.48-57, 2011.

L. N. Harris, N. Ismaila, L. M. Mcshane, F. Andre, D. E. Collyar et al., Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive Breast Cancer, Am Soc Clin Oncol Clin Prac Guideline, vol.34, pp.1134-50, 2016.

A. E. Giuliano, J. L. Connolly, S. B. Edge, E. A. Mittendorf, H. S. Rugo et al., Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, vol.67, pp.290-303, 2017.

C. Isaacs, V. Stearns, and D. F. Hayes, New prognostic factors for breast cancer recurrence, Semin Oncol, vol.28, pp.53-67, 2001.

M. Gnant, I. Sestak, M. Filipits, M. Dowsett, M. Balic et al., Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype, Ann Oncol, vol.26, pp.1685-91, 2015.

J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc et al., Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, vol.27, pp.1160-1167, 2009.

M. Filipits, T. O. Nielsen, M. Rudas, R. Greil, H. Stöger et al., The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrineresponsive early breast cancer, Clin Cancer Res, vol.20, pp.1298-305, 2014.

B. Wallden, J. Storhoff, T. Nielsen, N. Dowidar, C. Schaper et al., Development and verification of the PAM50-based Prosigna breast cancer gene signature assay, BMC Med Genomics, vol.8, p.54, 2015.

J. Bonneterre, A. Prat, P. Galván, P. Morel, and S. Giard, Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study, Curr Med Res Opin, vol.32, pp.835-839, 2016.

D. C. Allred, J. M. Harvey, M. Berardo, and G. M. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, vol.11, pp.155-68, 1998.

A. C. Wolff, M. Hammond, K. H. Allison, B. E. Harvey, P. B. Mangu et al., Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update, J Clin Oncol, vol.36, pp.2105-2127, 2018.

C. W. Elston, E. Io-;-van-diest, P. J. Baak, J. P. Matze-cok, P. Wisse-brekelmans et al., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.19, p.90313, 1991.

M. Dowsett, T. O. Nielsen, A. 'hern, R. Bartlett, J. Coombes et al., Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, vol.103, pp.1656-64, 2011.

A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.24, pp.206-229, 2013.

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, pp.8-30, 2015.

J. A. Sparano, R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain et al., Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, vol.379, pp.111-121, 2018.

F. Cardoso, L. J. Van't-veer, J. Bogaerts, L. Slaets, G. Viale et al., 70-Gene Signature as an Aid to treatment decisions in early-stage breast cancer, N Engl J Med, vol.375, pp.717-746, 2016.

I. Krop, N. Ismaila, F. Andre, R. C. Bast, W. Barlow et al., Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline focused update, J Clin Oncol, vol.35, pp.2838-2885, 2017.

M. Kwa, A. Makris, and F. J. Esteva, Clinical utility of gene-expression signatures in early stage breast cancer, Nat Rev Clin Oncol, vol.14, pp.595-610, 2017.

M. Dowsett, I. Sestak, E. Lopez-knowles, K. Sidhu, A. K. Dunbier et al., Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, vol.31, pp.2783-90, 2013.

J. M. Bartlett, J. Bayani, A. Marshall, J. A. Dunn, A. Campbell et al., Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others, J Natl Cancer Inst, vol.108, p.50, 2016.

A. Prat, A. Lluch, A. K. Turnbull, A. K. Dunbier, L. Calvo et al., A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse, Clin Cancer Res, vol.23, pp.3035-3079, 2017.

J. J. Gao and S. M. Swain, Luminal a breast cancer and molecular assays: a review, Oncologist, vol.23, pp.556-65, 2018.

M. C. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung et al., Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, vol.101, pp.736-50, 2009.

R. Conforti, T. Boulet, G. Tomasic, E. Taranchon, R. Arriagada et al., Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials, Ann Oncol, vol.18, pp.1477-1483, 2007.

C. D. Hart, G. Sanna, O. Siclari, L. Biganzoli, D. Leo et al., Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes, J Clin Oncol, vol.24, pp.1260-1263, 2012.

A. S. Coates, E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant et al., Tailoring therapies -improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.26, pp.1533-1579, 2015.

A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann et al., Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.22, pp.1736-1783, 2011.

G. Curigliano, H. J. Burstein, E. P. Winner, M. Gnant, P. Dubsky et al., De-escalating and escalating treatments for early-stage breast cancer: the St, Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer, vol.28, pp.1700-1712, 2017.

G. Ciriello, R. Sinha, K. A. Hoadley, A. S. Jacobsen, B. Reva et al., The molecular diversity of Luminal A breast tumors, Breast Cancer Res Treat, vol.141, pp.409-429, 2013.

J. Pérez-peña, A. Alcaraz-sanabria, C. Nieto-jiménez, R. Páez, V. Corrales-sánchez et al., Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors, Oncotarget, vol.8, pp.21733-21773, 2017.

A. V. Laenkholm, D. Grabau, M. L. Møller-talman, E. Balslev, B. Jylling et al., An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG), Acta Oncol, vol.57, pp.83-92, 2018.

F. Penault-llorca and N. Radosevic-robin, Ki67 assessment in breast cancer: an update, Pathology, vol.49, pp.166-71, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01675161

D. L. Rimm, S. Leung, L. M. Mcshane, Y. Bai, A. L. Bane et al., An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer, Mod Pathol, vol.32, pp.59-69, 2018.

I. Skaland, P. J. Van-diest, E. A. Janssen, E. Gudlaugsson, and J. P. Baak, Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years, Hum Pathol, vol.39, pp.584-90, 2008.